Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for transplantation.

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance Paris, October 25, 2024 Q3 sales growth of 15. ...

Sanofi SAN-1.32%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this immunization to ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.